Crescendo Biologics will apply antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to generate high-affinity human heavy chain antibodies that yield human heavy chain (VH) fragments that have no requirement for humanization. This is combined with in vitro ribosome display technology for antibody optimization.
Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT United Kingdom +44 (0) 1223 497140 http://www.crescendobiologics.com Mike Romanos +44(0)1223-497140
Company Facts
Founded:
Founders:
CEO:
Mike Romanos
CTO or technical lead:
CFO or finance director:
Head of Sales:
Head of Marketing:
Stage:
Growth
Category:
Biotechnology & Healthcare
Sector:
Biopharmaceuticals
Employees:
Profitability:
Funding raised:
Yes
Funding sought:
Seeking Partnerships:
Non-executive Board Members
Key Customers
Key Business Partners
Key Competitors
Capital Raised
Date
Size
Investors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.
To read more about the Online data service click here
Public Offerings
Date
Type
Exchange
No public offerings
Data
27,633 Tech investments From our Online Data Service
